Return to homepagePandemic Pact

Design and development of mucosal vaccine vectors in commensal bacteria expressing SARS-CoV-2 antigens - a potential prophylactic method

  • Funded by National Research Foundation of Korea (NRF), Swedish Research Council
  • Total publications:2 publications

Grant number: 2020-06320

Grant search

Key facts

  • Disease

    COVID-19

  • Known Financial Commitments (USD)

    $180,000

  • Funder

    National Research Foundation of Korea (NRF), Swedish Research Council

  • Principal Investigator

    Lars Engstrand

  • Research Location

    Sweden

  • Lead Research Institution

    Karolinska Institutet

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    Innovation

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Medical biotechnology (specializing in cell biology (incl. Stem cell biology), molecular biology, microbiology, biochemistry or biopharmacy)

Publicationslinked via Europe PMC

Last Updated:2 days ago

View all publications at Europe PMC

Oral Immunisation With Non-GMO Surface Displayed SARS-CoV-2 Spike Epitopes on Bacteria-Like Particles Provokes Robust Humoral and Cellular Immune Responses, and Modulated the Gut Microbiome in Mice.

Hacking Commensal Bacteria to Consolidate the Adaptive Mucosal Immune Response in the Gut-Lung Axis: Future Possibilities for SARS-CoV-2 Protection.